Prof Dr YORINOBU MAEDA, Fukuyama university, Japan
Prof. Dr. Yorinobu Maeda, Ph.D. (Hiroshima University, 1990), is a renowned expert in drug safety, pharmacokinetics, and infection control. As a professor at Fukuyama University and Drug Safety Director, he has advanced renal function-based dosing and prescription optimization. His contributions have earned him multiple awards, including Best Paper Awards (2001, 2005) and an Academic Contribution Award (2014) from the Japanese Society of Pharmaceutical Health Care and Sciences. With a strong academic and clinical impact, Dr. Maeda is a leading figure in pharmaceutical advancements, ensuring better patient safety and treatment efficacy. 🏅🔬
Publication Profile
scopus
Educational and Professional Background
Prof. Dr. Yorinobu Maeda has a distinguished background in pharmaceutical sciences, earning his Ph.D. from Hiroshima University in 1990 🎓. His expertise spans infection control, hospital pharmacy specialization, and drug safety leadership, reflecting his dedication to pharmaceutical advancements 💊. With leadership roles in major hospitals 🏥 and an esteemed position as a professor at Fukuyama University 🎓, he has made significant academic and practical contributions to the field. His work continues to shape the future of pharmacy, ensuring patient safety and advancing healthcare practices for better medical outcomes 🌍🔬.
Contributions to Pharmaceutical Sciences
Prof. Dr. Yorinobu Maeda has made significant contributions to pharmaceutical sciences, particularly in drug safety, pharmacokinetics, and dosage optimization 💊🔬. His research focuses on infection control 🦠, renal function-based dosing 🏥, and improving prescription practices, directly enhancing patient safety and treatment efficacy 👨⚕️✅. As a Drug Safety Director, he plays a crucial role in advancing pharmaceutical practices, ensuring medications are used effectively and safely. His dedication to optimizing drug therapy and refining medical protocols continues to have a lasting impact on healthcare, improving outcomes for patients worldwide 🌍💉.
Awards and Recognitions
Prof. Dr. Yorinobu Maeda has made remarkable contributions to the field of pharmaceutical healthcare, earning numerous prestigious accolades from the Japanese Society of Pharmaceutical Health Care and Sciences. His achievements include the Best Paper Awards in 2001 and 2005 🏆, as well as the esteemed Academic Contribution Award in 2014 🎓. These honors highlight his dedication to advancing research and implementing pharmacokinetic principles to enhance patient safety and care 🩺. Dr. Maeda’s work stands as a testament to his unwavering commitment to improving healthcare standards and fostering innovation in pharmaceutical sciences. 🌟
Research Focus
Professor Dr. Yorinobu Maeda is an eminent researcher specializing in pharmaceutical sciences, with a primary focus on drug bioavailability, prodrug development, and therapeutic drug monitoring. His work spans areas such as drug absorption, small intestinal bacterial overgrowth diagnosis, and managing adverse drug reactions. Notable research includes the impact of metal ions on drug efficacy and innovative prodrug strategies. Through collaborative studies, he contributes to optimizing drug delivery systems and clinical pharmacotherapy, enhancing patient safety and treatment outcomes. 🧪💊
Publication Top Notes
5-Aminosalicylic Acid Distribution into the Intestinal Membrane Along the Gastrointestinal Tract After Oral Administration in Rats
Development and Evaluation of EDTA-Treated Rabbits for Bioavailability Study of Chelating Drugs Using Levofloxacin, Ciprofloxacin, Hemiacetal Ester Prodrugs, and Tetracycline
Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth
Ester Prodrugs of Levofloxacin to Prevent Chelate Formation in Presence of Aluminium Ion
Study on the method to avoid infusion‑site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells
Effect of aluminium ion on bioavailability of levofloxacin following oral administration of cilexetil ester of levofloxacin as prodrug in rats